Trans Genic Inc., headquartered in Fukuoka with roots in advanced animal genetics, is a cutting-edge contract research organization specializing in the discovery and development of human monoclonal antibodies through transgenic platforms. Leveraging proprietary transgenic mice engineered with full-length human immunoglobulin loci, the company enables in vivo generation of fully human antibodies without requiring subsequent humanization—producing naturally affinity-matured, high-quality antibodies directly through immune response
creative-biolabs.com
. By integrating human V(D)J heavy and light chain constructs into the mouse genome while silencing endogenous immunoglobulin expression, Trans Genic’s platforms harness natural B-cell selection and somatic hypermutation, yielding therapeutic-grade antibodies with reduced immunogenicity and reliable biophysical characteristics
link.springer.com
. These antibodies are discovered via established hybridoma and single-cell screening approaches, streamlining candidate identification for downstream development. Through this human antibody-producing technology, Trans Genic provides pharmaceutical and biotech partners with fully human monoclonal antibodies that are primed for therapeutic development, making it a preeminent CRO in biologics discovery.
